The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells

被引:89
作者
Baptiste, N
Friedlander, P
Chen, XB
Prives, C [1 ]
机构
[1] Columbia Univ, Dept Biol Sci, New York, NY 10027 USA
[2] Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA
关键词
p53; apoptosis; anti-neoplastics; proline-rich domain;
D O I
10.1038/sj/onc/1205015
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In some cell types either DNA damage or p53 expression leads to minimal cell death, while combining the two leads to a strong apoptotic response. To further understand features of p53 that contribute to this increased cell death we used clones of H1299 cells that express wild-type or several mutant forms of p53 under a tetracycline-regulated promoter. In these cells the induction of wildtype p53 leads to significant apoptosis only when combined with exposure to a number of chemotherapeutic agents. A common target of p53, p21, is itself not sufficient to cause apoptosis in the presence of these chemotherapeutic compounds. Many agents also effectively increase cell death when a transcriptionally-defective p53, p53([gln22ser23]), is induced, although a dramatic exception is treatment with 5-FU, which strongly cooperates with wild-type but not p53([gln22ser23]). Our results with 5-FU thus show that genetically separable functions of p53 are involved in its ability to respond to DNA-damaging agents to induce apoptosis. Notably as well, deleting the C-terminal 30 amino acids of p53 does not affect this cooperative effect with DNA-damaging agents. By contrast, a p53 mutant lacking the PXXP-domain between residues 60-90, while at least partially transcriptionally-competent, cannot be rendered apoptotic by any compounds that we tested. Thus the PXXP domain provides an essential component of the ability of p53 to respond to DNA-damaging agents to cause cell death.
引用
收藏
页码:9 / 21
页数:13
相关论文
共 115 条
[41]   INDUCTION OF APOPTOSIS IN HELA-CELLS BY TRANS-ACTIVATION-DEFICIENT P53 [J].
HAUPT, Y ;
ROWAN, S ;
SHAULIAN, E ;
VOUSDEN, KH ;
OREN, M .
GENES & DEVELOPMENT, 1995, 9 (17) :2170-2183
[42]   14-3-3σ is a p53-regulated inhibitor of G2/M progression [J].
Hermeking, H ;
Lengauer, C ;
Polyak, K ;
He, TC ;
Zhang, L ;
Thiagalingam, S ;
Kinzler, KW ;
Vogelstein, B .
MOLECULAR CELL, 1997, 1 (01) :3-11
[43]   ACTIVATION OF P53 SEQUENCE-SPECIFIC DNA-BINDING BY SHORT SINGLE STRANDS OF DNA REQUIRES THE P53 C-TERMINUS [J].
JAYARAMAN, L ;
PRIVES, C .
CELL, 1995, 81 (07) :1021-1029
[44]   Covalent and noncovalent modifiers of the p53 protein [J].
Jayaraman, L ;
Prives, C .
CELLULAR AND MOLECULAR LIFE SCIENCES, 1999, 55 (01) :76-87
[45]   A transactivation-deficient mouse model provides insights into Trp53 regulation and function [J].
Jimenez, GS ;
Nister, M ;
Stommel, JM ;
Beeche, M ;
Barcarse, EA ;
Zhang, XQ ;
O'Gorman, S ;
Wahl, GM .
NATURE GENETICS, 2000, 26 (01) :37-43
[46]   A MAMMALIAN-CELL CYCLE CHECKPOINT PATHWAY UTILIZING P53 AND GADD45 IS DEFECTIVE IN ATAXIA-TELANGIECTASIA [J].
KASTAN, MB ;
ZHAN, QM ;
ELDEIRY, WS ;
CARRIER, F ;
JACKS, T ;
WALSH, WV ;
PLUNKETT, BS ;
VOGELSTEIN, B ;
FORNACE, AJ .
CELL, 1992, 71 (04) :587-597
[47]   p53: Puzzle and paradigm [J].
Ko, LJ ;
Prives, C .
GENES & DEVELOPMENT, 1996, 10 (09) :1054-1072
[48]  
Kobayashi T, 1995, ONCOGENE, V11, P2311
[49]   A p53-independent damage-sensing mechanism that functions as a checkpoint at the G(1)/S transition in Chinese hamster ovary cells [J].
Lee, HY ;
Larner, JM ;
Hamlin, JL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (02) :526-531
[50]   P53 AND ITS 14 KDA C-TERMINAL DOMAIN RECOGNIZE PRIMARY DNA-DAMAGE IN THE FORM OF INSERTION DELETION MISMATCHES [J].
LEE, S ;
ELENBAAS, B ;
LEVINE, A ;
GRIFFITH, J .
CELL, 1995, 81 (07) :1013-1020